A Phase 1b/2 Study of CTD402 in T-ALL/LBL Patients

Recruiting Phase 1,Phase 2 NCT07070219

Study Description

A Clinical Trial to Evaluate the Safety and Effectiveness of CTD402 in Treating Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Study Details

Registry ID:: NCT07070219
Conditions:: Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic
Phase:: Phase 1,Phase 2
Target Enrollment:: 118 participants
Start Date:: October 7, 2025
Age Range:: 1–999 years
Healthy Volunteers:: No

Study Locations (8 sites)

Montefiore Einstein Comprehensive Cancer Center
The Bronx, New YorkUnited States, United States
Memorial Sloan Kettering Cancer Center
New York, New YorkUnited States, United States
Sarah Cannon Research Insitute
Nashville, TennesseeUnited States, United States
University of Chicago
Chicago, IllinoisUnited States, United States
MD Anderson Cancer Center
Houston, TexasUnited States, United States
Mayo Clinic - Rochester
Rochester, MinnesotaUnited States, United States
Stanford University
Palo Alto, CaliforniaUnited States, United States
Royal Prince Alfred
Sydney, New South WalesAustralia, Australia

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →